Cell and gene therapy 2.0 dominates latest round of biotech IPOs in scramble for a $300M-plus Nasdaq windfall

Back at the start of January last year, Poseida Therapeutics thought it had an IPO-worthy game plan that would sell on Wall Street. Instead, with the market in something of a dyspeptic mood, the San Diego-based startup with its next-gen approach to cell and gene therapy switched to a Series…